Genmab — Oktober 2020
-
God morgen.
-
God morgen
-
-
sorry, thought you posted the presentation https://www.novartis.com/sites/www.novartis.com/files/q3-2020-investor-presentation.pdf
-
Ikke meget fest over kursen i dag. Skulle den ikke stige op mod uge 46 med outstanding nyheder/data?
-
Jeps...og trærystere..:-D
-
Mon ikke snart de bliver træt i armene?
-
-
yes, that is this quote: Kesimpta (ofatumumab, formerly OMB157) was launched in the US following FDA approval in August.
Kesimpta is a targeted B-cell therapy that can deliver powerful and sustained high efficacy, with a
favorable safety profile and the flexibility of an at home self-administration for a broad population of RMS
patients. We have seen a promising start with our flexible hybrid face-to-face / digital launch. -
To provide
access to eligible US patients while they obtain reimbursement we are providing Kesimpta free of charge
for a limited amount of time. Based on our assumption on the time from initiation of therapy to
reimbursement we anticipate that a majority of the sales in the first quarter of launch will be free goods
and have accrued accordingly. We expect this share to decrease over time as reimbursement
progresses
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind